Growtropin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Growtropin

What is Growtropin? Definition and Classification

Property Description
Active ingredient Somatropin
Form Lyophilized powder for injection / Solution for injection
Pharmacological class Pituitary and Hypothalamic Hormones and Analogues
Common use Supports growth, tissue maintenance, and metabolism
Origin Synthetic (Recombinant DNA Technology)

Growtropin is a specific prescription-only medicine whose active ingredient is Somatropin. It is officially classified as a Growth Hormone Analogue and belongs to the larger class of Pituitary and Hypothalamic Hormones and Analogues. This classification reflects its role as a therapeutic hormone substitute.

Somatropin is chemically and functionally identical to the human growth hormone (hGH) naturally produced by the pituitary gland. Like the natural hormone, Somatropin is a Peptide hormone, requiring the injectable route of administration because its protein structure would be deactivated by the digestive system.

Composition and Origin: The Recombinant Type

The Somatropin contained in Growtropin is a synthetic form known as Recombinant Human Growth Hormone (rhGH). This compound is manufactured through modern Recombinant DNA technology in a laboratory setting.

This biotechnological origin is a key differentiating factor, as this manufacturing process is designed to yield a structurally precise, high-purity product. Recombinant Human Growth Hormone is used for long-term treatment of growth failure due to various conditions. The product is typically supplied as a Lyophilized powder for injection which is dissolved before use, or as a ready-to-use liquid solution for injection.

General Function and Purpose of Somatropin

The fundamental function of Somatropin is to act as a primary regulator of development, tissue repair, and metabolism. Its action is associated with initiating anabolic action, signaling the body to build up proteins in tissues, muscles, and bones.

The substance also produces a systemic metabolic effect, influencing how the body processes fats and sugars for energy. The general purpose of administering Growtropin is to provide the necessary hormonal signals to support and maintain proper physiological structure, development, and energy balance when natural hormone production is inadequate.

Regulatory References

  1. NIH: Physiology, Growth Hormone

What side effects are possible with Growtropin?

Possible Side Effects and Safety Information

The safety profile of Growtropin (Somatropin) is defined by regulatory bodies based on classified adverse reactions and specific usage restrictions. Side effects are organized by frequency and the body system affected, providing a formal overview of documented risks.

For adults receiving replacement therapy, Very Common reactions include arthralgia (joint pain), myalgia (muscle pain), and headache. Common adverse reactions often relate to fluid retention, such as peripheral edema, paraesthesia (tingling), and carpal tunnel syndrome. These fluid retention symptoms are documented as most frequent at the start of treatment and are often dose-dependent.

Adverse effects are documented across various System Organ Classes, including Nervous System Disorders (e.g., headache, intracranial hypertension), Musculoskeletal Disorders, and Metabolism and Nutrition Disorders (e.g., fluid retention).

Serious adverse reactions officially highlighted in regulatory information, though less common, include Intracranial Hypertension and potential risks regarding malignancy recurrence or development in susceptible individuals. Pediatric patients may experience an increased risk of orthopedic issues like Slipped Capital Femoral Epiphysis during periods of rapid growth.

Population-specific safety considerations are noted, such as a high-risk warning for patients with Prader-Willi Syndrome who have severe obesity or respiratory impairment. Furthermore, the label explicitly states that use is contraindicated in patients with evidence of active malignancy or acute critical illness following major trauma or surgery.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Growtropin

The official overdose profile for Growtropin (somatropin) is defined by regulatory bodies based on the duration of overexposure and the required emergency response.

Category Officially Documented Manifestations
Short-Term Overdose Acute overexposure may initially present as hypoglycemia (low blood sugar), followed by subsequent hyperglycemia. Other documented signs include tremors, cold sweats, headache, dizziness, weakness, and fluid retention (edema).
Long-Term Overdose Chronic administration exceeding prescribed doses results in clinical outcomes consistent with excess growth hormone. This is manifested as gigantism in children whose growth plates remain open, and acromegaly in adults or patients whose growth plates are fused.

Emergency Response and Management Regulator-Mandated Action
When to Seek Urgent Help Individuals must seek emergency medical attention or call the Poison Help line immediately upon the suspicion of overdose.
Overdose Management Management is restricted to providing symptomatic and supportive treatment to address the manifested clinical signs and metabolic imbalances. No specific antidote is known for somatropin overdosage.

The regulatory documentation establishes two distinct categories of risk: acute, transient metabolic disturbances and severe, chronic somatic growth abnormalities. This structure mandates immediate emergency action, explicitly defining the conditions under which external medical help must be sought. Treatment, as documented, focuses strictly on the resulting symptoms, given the absence of a known reversing agent.

Therapeutic Uses of Growtropin

Quick Facts: Uses of Growtropin

  • Pediatric Uses: May support growth in children diagnosed with growth failure due to inadequate endogenous growth hormone secretion.
  • Genetic Conditions: May be used to manage short stature associated with certain genetic syndromes, including Turner syndrome and Prader-Willi syndrome.
  • Other Indications: May also be prescribed for growth failure related to chronic kidney disease and for individuals born small for gestational age who do not demonstrate appropriate catch-up growth.
  • Adult Uses: May be used as replacement therapy for adults with documented growth hormone deficiency (GHD).

Growtropin is a prescription medication utilized in both pediatric and adult patient populations to manage specific conditions associated with growth and metabolic function. In children, the primary therapeutic application is to address growth failure resulting from an inadequate secretion of native growth hormone, which may support expected growth and development. It is also an established treatment option for managing short stature in children with Turner syndrome, Noonan syndrome, Prader-Willi syndrome, and Idiopathic Short Stature (ISS), provided the growth plates are not closed. The medication may also be used for patients born small for gestational age who experience continued growth challenges.

For adults, Growtropin serves as a replacement for endogenous growth hormone in individuals with diagnosed Growth Hormone Deficiency (GHD). Therapy for adults with GHD may support improvements in body composition and bone density.

Growtropin is available for several therapeutic indications.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Regulatory documentation for Growtropin (Somatropin) strictly defines the patient populations eligible for its use and lists several absolute contraindications where the medicine must not be used.

Classification Patient Status
Allowed Populations Patients (pediatric and adult) who meet specific diagnostic criteria for growth failure or related conditions as specified in the official labeling.
Contraindicated Patients with Active Malignancy or a history of malignancy whose treatment is not yet complete.
Contraindicated Patients with Acute Critical Illness due to complications from major surgery, multiple trauma, or acute respiratory failure.
Contraindicated Patients with Active Proliferative or Severe Non-Proliferative Diabetic Retinopathy.
Contraindicated Pediatric patients whose growth plates (epiphyses) have closed (fused), preventing further linear growth.
Contraindicated Pediatric patients with Prader-Willi Syndrome who are severely obese or have a history of upper airway obstruction, sleep apnea, or severe respiratory impairment.

For pediatric patients with Prader-Willi Syndrome, a full evaluation for airway obstruction and sleep apnea is required before treatment begins, and the medicine must be discontinued if such issues arise during therapy. Treatment for growth promotion is limited by skeletal maturity and must be stopped upon closure of the epiphyses.

What should I know about interactions with other medicines?

Growtropin’s active ingredient, Somatropin, is officially documented to interact with several classes of medicinal products by affecting hormonal balance and liver enzyme activity.

Formal Restrictions and High-Level Interactions

  • Contraindicated Combination: Use is formally prohibited in patients experiencing Acute Critical Illness (e.g., following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure).
  • Hormone Counter-Regulation: Somatropin is documented to decrease insulin sensitivity. Consequently, co-administration with Insulin and/or other Hypoglycemic Agents may necessitate an adjustment to the dose of the anti-diabetic medication.
  • Glucocorticoids: Pharmacologic doses of glucocorticoids are officially stated to attenuate the growth-promoting effects of somatropin in pediatric patients. Somatropin's inhibition of the 11β-Hydroxysteroid Dehydrogenase Type 1 (11βHSD-1) enzyme can also unmask previously undiagnosed central hypoadrenalism or necessitate an increase in the replacement dose of glucocorticoids.

Metabolic and Exposure Alterations

  • Cytochrome P450-Metabolized Drugs: Somatropin may alter the clearance of compounds metabolized by the CYP450 liver enzyme system, including specific examples like corticosteroids, sex steroids, anticonvulsants, and cyclosporine. Careful monitoring is advised when these drugs are co-administered.
  • Oral Estrogen: Women taking Oral Estrogen replacement therapy may require a larger dose of somatropin to achieve their defined treatment goal.

Population-Specific Notes

Official labeling notes that elderly patients may exhibit increased sensitivity to the effects of somatropin. There are no explicitly documented timing separation requirements or formal interactions with food, alcohol, or herbal products in regulatory prescribing information.

Mechanism of Action

Growtropin is a recombinant polypeptide that functions as an agonist at the Growth Hormone Receptor (GHR), which is expressed on the surface of various tissues, notably hepatocytes and chondrocytes. Binding of the drug to the GHR causes receptor dimerization and activation of the intracellular Janus Kinase 2 (JAK2).

JAK2 is a non-receptor tyrosine kinase that, upon activation, cross-phosphorylates itself and subsequently phosphorylates key tyrosine residues on the GHR cytoplasmic tail. This phosphorylation initiates the binding and activation of various intracellular signaling molecules, primarily Signal Transducer and Activator of Transcription (STAT) proteins, such as STAT5b. Activated STAT5b translocates to the nucleus to modify gene transcription. A primary transcriptional consequence is the increased synthesis and secretion of Insulin-like Growth Factor-I (IGF-I), predominantly by the liver, which then acts on its own receptors (IGF-1R) in peripheral tissues. IGF-I and direct GHR signaling modulate protein synthesis and cellular proliferation, resulting in system-level physiological changes, including altered protein metabolism, lipid mobilization, and increased linear skeletal growth at the epiphyseal plates.

Dosage and Administration Information

Administration Overview

Growtropin is administered via subcutaneous injection, typically delivered into the fatty tissue just beneath the skin. Common injection sites include the abdomen, thighs, or upper arms. It is important to rotate the injection sites daily to minimize the risk of localized tissue irritation or lipoatrophy.

Preparation of the Solution

Prior to administration, the medication must be prepared according to the specific format provided (vial or pre-filled pen). If the medication requires reconstitution, a diluent is gently added to the powder. The vial should be swirled with a slow, gentle motion until the powder is completely dissolved. Aggressive shaking of the vial must be avoided, as this can denature the protein and render the medication ineffective. The final solution should be clear and colorless; if the solution is cloudy or contains particulate matter, it should not be used.

Technical Procedure

  1. Preparation: Wash hands thoroughly and gather the necessary supplies, including the medication, a sterile syringe or needle, and alcohol swabs.
  2. Site Cleaning: Clean the chosen injection site with an alcohol swab and allow the skin to air dry.
  3. Injection: Pinch a fold of skin and insert the needle at the recommended angle (usually 45 to 90 degrees). Depress the plunger or activation button steadily to deliver the dose.
  4. Completion: Withdraw the needle and apply gentle pressure to the site with a clean gauze pad if necessary. Do not rub the area.

Storage and Handling

Proper temperature maintenance is essential for preserving the stability of the medication. Unused Growtropin should be kept refrigerated. After the first use or reconstitution, the medication remains stable for a specific window of time when stored under refrigeration. The solution should be protected from direct light and should never be frozen.

Recent Clinical Evidence

Research evidence / Overview of Studies for Growtropin


Evidence for Use in Pediatric Growth Hormone Deficiency (GHD)

The research base for Growtropin in children with Growth Hormone Deficiency (GHD) relies on Randomized Controlled Trials (RCTs) and long-term observational patient registries. These studies were designed to examine how treatment relates to growth patterns in children and adolescents whose pituitary glands do not secrete enough native growth hormone.

Studies examined patterns in Annual Height Velocity (HV) during the first year of treatment compared to pre-treatment periods. Long-term research describes the Near-Adult Height observed in patients who completed the study protocol. Research recognizes adherence to the daily injection regimen as a variable studied in relation to long-term outcomes.


Evidence for Use in Adult Growth Hormone Deficiency (GHD)

Research for adults with GHD involves placebo-controlled RCTs and very large, multi-center observational registries. These studies evaluated outcomes of Growtropin as hormone replacement therapy. Researchers focused on outcomes related to Body Composition, Bone Mineral Density (BMD), and cardiovascular risk markers.

Controlled trials reported measurements that describe changes in Body Composition after several months of treatment. Research related to Quality of Life measures reported mixed findings across different trials and assessment tools. Few studies have the long duration necessary to monitor long-term outcomes such as fractures or cardiovascular disease events.


What Is Still Uncertain About Growtropin

Despite the evidence, research highlights areas where data are still emerging or remain limited:

  • Certainty remains low for certain key adult outcomes, such as long-term data related to fractures or cardiovascular events.
  • Data are still emerging for certain populations, such as specific outcomes in older adults with GHD and the very long-term outcomes for children studied for short stature conditions.

Key Studies & References

  1. Somatropin Injection: MedlinePlus Drug Information (NIH)
  2. growth hormone 1 (Somatropin) | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY (PubChem)

Frequently Asked Questions (FAQ)

Common questions about Growtropin (FAQ)


Q: Can Growtropin affect my sleep?

Regulatory documents list central nervous system effects, such as headaches and increased pressure around the brain (Intracranial Hypertension), as possible adverse reactions. Additionally, changes in sleep, including sleep apnea, have been noted in safety warnings for specific groups like pediatric patients with Prader-Willi Syndrome.


Q: Can taking Growtropin change my mood or energy levels?

Adverse reaction lists provided in official documents sometimes include general feelings of discomfort that could be linked to mood or energy, such as tiredness, irritability, or discouragement. These reports are often classified as general symptoms rather than specific psychiatric effects.


Q: Is it true that Growtropin can interact with common pain relievers?

Regulatory documents indicate that somatropin may alter the way the body processes certain drugs metabolized by the CYP450 liver enzyme system. This includes some non-steroidal anti-inflammatory drugs (NSAIDs) used as common pain relievers, which may have reduced levels in the blood. The official prescribing information indicates that caution is advised when these two types of medications are used together.


Q: What happens if I accidentally miss a dose of Growtropin?

Regulatory guidance states that if a dose is missed, immediate consultation with the prescribing doctor or pharmacist for specific instructions is required. The medicine must be used exactly as prescribed by your physician.


Q: Do I need to change my diet while taking Growtropin?

Official documents note that somatropin is documented to decrease the body's sensitivity to insulin, which can impact blood sugar management and may be relevant to dietary choices. Furthermore, official documents note that for patients with specific underlying conditions like Prader-Willi Syndrome, maintaining effective weight control during therapy is advised.


Q: Can people with high blood pressure use Growtropin?

Somatropin can cause fluid retention and swelling (edema) as a common side effect, particularly when treatment begins. This fluid retention can contribute to or worsen high blood pressure (hypertension). Official documentation indicates that patients with pre-existing high blood pressure are often subject to close monitoring and advised caution.


Q: What kind of monitoring is done while someone is on Growtropin?

Official prescribing information indicates that patients typically undergo periodic medical monitoring. This commonly includes checks of blood sugar and thyroid hormone levels, as somatropin can affect both. Monitoring often includes checks for signs of conditions such as Intracranial Hypertension or hypoadrenalism.


Q: What does 'contraindication' mean in the context of Growtropin?

A contraindication is a concept used in official medical labeling to describe a specific medical condition or situation where the use of the drug is formally prohibited because of the potential for harm. For Growtropin, examples of these strict rules include having active cancer or acute critical illness.


Q: How is Growtropin different from similar-sounding non-prescription products?

Growtropin’s active ingredient is Somatropin, a protein that is chemically and functionally identical to the human growth hormone made naturally in the body. As a specialized, pure recombinant peptide hormone, it is regulated as a prescription-only medicine and is not available over the counter.


Q: Will taking Growtropin help me gain muscle mass?

According to official scientific and clinical sections, Somatropin stimulates anabolic action, which promotes protein synthesis in tissues and muscles. Studies indicate that it can improve lean body mass in adults with growth hormone deficiency. It is also officially indicated for the treatment of wasting or cachexia associated with HIV.


Q: Does Growtropin make you feel hungry?

Official adverse reaction lists do not consistently or explicitly note increased hunger as a common side effect. However, a documented but less common side effect reported in some studies is loss of appetite (anorexia).


Q: Why are people with kidney issues sometimes ineligible for Growtropin?

Regulatory documentation notes that Somatropin has not been thoroughly studied in patients with severe renal impairment (kidney damage). Conversely, the drug is sometimes indicated for pediatric growth failure specifically caused by chronic kidney disease. This indicates that eligibility is complex and requires clinical assessment of the individual patient's specific kidney condition.


Q: Is there a risk of developing a serious allergic reaction to Growtropin?

Yes, regulatory safety information explicitly lists the risk of severe hypersensitivity (serious allergic reactions). The product is formally contraindicated for use in patients who have a known hypersensitivity to somatropin or any of the inactive components of the drug formulation.


Q: Can taking Growtropin affect fertility?

Official human data on the direct effect of Growtropin on fertility are limited. Nonclinical toxicology studies, which involve animal testing to evaluate potential effects on reproduction and fertility, are typically summarized in the regulatory documents.


Q: What if I'm taking multiple medications; how do I check for interactions with Growtropin?

The official labels state that your physician may need to adjust the doses of other medications to avoid interactions. Drug classes that commonly require monitoring include insulin, other diabetic agents, glucocorticoids, and certain drugs metabolized by the CYP450 liver system. Regulatory requirements emphasize the importance of maintaining a complete and updated list of all medications for your prescribing physician.


Q: Why is it important to follow the recommended schedule for Growtropin?

Official prescribing information states that the dose and frequency of administration are highly individualized and based on a patient's specific condition and response to therapy. Therefore, following the prescribed schedule is important for supporting the intended therapeutic outcome.


Q: Can people with thyroid problems use Growtropin?

Yes, but official safety warnings note that somatropin can cause low thyroid hormone levels (hypothyroidism). Patients with pre-existing thyroid problems or those receiving treatment for them should be monitored closely, as their replacement therapy may be subject to adjustment based on official monitoring.


Q: What kind of specialists typically prescribe Growtropin?

Growtropin is a specialized prescription product for hormonal deficiencies and related conditions. Because of its specific function and monitoring requirements, treatment is typically managed by a physician who specializes in the endocrine (hormone) system, such as an endocrinologist.


Q: Is Growtropin used for anything other than growth-related conditions?

Yes, the active ingredient, somatropin, is officially approved by regulatory bodies for use in adults with specific non-growth conditions. This includes the treatment of wasting syndrome or cachexia associated with HIV, and for certain forms of Short Bowel Syndrome (SBS).


Q: Is it normal to feel nervous or anxious when starting a drug like Growtropin?

Official adverse event reports sometimes list general emotional or psychological symptoms, such as irritability or discouragement. While not explicitly listed as common anxiety symptoms, official information indicates that any new or concerning emotional feelings should be discussed with a healthcare provider.

How should Growtropin be stored and disposed of?

Storage and Disposal Requirements for Growtropin (Somatropin)

Official labeling mandates specific conditions to maintain the stability of somatropin. The unreconstituted powder must be stored under refrigeration at 2 C to 8 C (36 F to 46 F) and protected from light. The product must not be frozen.

Once the powder is mixed, the reconstituted solution must also be refrigerated between uses, and it must not be shaken. The solution's shelf-life is strictly limited to 28 days (multi-dose) or 24 hours (single-dose) after mixing, and any unused portion must be discarded after this period.

All used needles, syringes, and cartridges are classified as sharps and must be disposed of immediately in an FDA-cleared sharps disposal container. Injection components must not be thrown into household trash. All medication and sharps containers must be kept out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Growtropin found in:

A-Z Index: